Cardiff Oncology Management

Management criteria checks 3/4

Cardiff Oncology's CEO is Mark Erlander, appointed in May 2020, has a tenure of 4.67 years. total yearly compensation is $1.55M, comprised of 38.4% salary and 61.6% bonuses, including company stock and options. directly owns 0.048% of the company’s shares, worth €97.55K. The average tenure of the management team and the board of directors is 3 years and 10.4 years respectively.

Key information

Mark Erlander

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage38.4%
CEO tenure4.7yrs
CEO ownership0.05%
Management average tenure3yrs
Board average tenure10.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mark Erlander's remuneration changed compared to Cardiff Oncology's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$43m

Jun 30 2024n/an/a

-US$41m

Mar 31 2024n/an/a

-US$40m

Dec 31 2023US$2mUS$594k

-US$41m

Sep 30 2023n/an/a

-US$41m

Jun 30 2023n/an/a

-US$40m

Mar 31 2023n/an/a

-US$39m

Dec 31 2022US$2mUS$571k

-US$39m

Sep 30 2022n/an/a

-US$39m

Jun 30 2022n/an/a

-US$38m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$4mUS$533k

-US$28m

Sep 30 2021n/an/a

-US$25m

Jun 30 2021n/an/a

-US$23m

Mar 31 2021n/an/a

-US$24m

Dec 31 2020US$1mUS$445k

-US$23m

Sep 30 2020n/an/a

-US$20m

Jun 30 2020n/an/a

-US$20m

Mar 31 2020n/an/a

-US$17m

Dec 31 2019US$853kUS$399k

-US$17m

Sep 30 2019n/an/a

-US$17m

Jun 30 2019n/an/a

-US$16m

Mar 31 2019n/an/a

-US$19m

Dec 31 2018US$909kUS$387k

-US$19m

Compensation vs Market: Mark's total compensation ($USD1.55M) is above average for companies of similar size in the German market ($USD837.57K).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.


CEO

Mark Erlander (64 yo)

4.7yrs

Tenure

US$1,547,772

Compensation

Dr. Mark Erlander, Ph D., is Chief Executive Officer of Cardiff Oncology, Inc. (formerly known as TrovaGene, Inc.) since May 2020 and was its Chief Scientific Officer March 4, 2013 to April 2020. Dr. Erlan...


Leadership Team

NamePositionTenureCompensationOwnership
Mark Erlander
CEO & Director4.7yrsUS$1.55m0.048%
€ 97.5k
James Levine
Chief Financial Officer3.5yrsUS$917.72k0.13%
€ 269.8k
Fairooz Kabbinavar
Chief Medical Officer1.9yrsUS$1.26m0%
€ 0
Tod Smeal
Chief Scientific Officer3yrsUS$4.17m0%
€ 0
Elizabeth Anderson
VP of Finance & Administration9.5yrsno datano data
Brigitte Lindsay
Senior Vice President of Finance2yrsno datano data
Charles Monahan
Senior Vice President of Regulatory Affairs3yrsno datano data

3.0yrs

Average Tenure

61.5yo

Average Age

Experienced Management: XE7C's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mark Erlander
CEO & Director4.6yrsUS$1.55m0.048%
€ 97.5k
Charles Cantor
Member of Scientific Advisory Boardno datano datano data
Gary Pace
Independent Director4.8yrsUS$114.43k2.07%
€ 4.2m
K. Hirth
Member of Scientific Advisory Board10.4yrsno datano data
Paul Billings
Member of Scientific Advisory Board12.2yrsUS$35.85kno data
Rodney Markin
Independent Chairman of the Board10.9yrsUS$154.43k0.061%
€ 123.7k
Carlo Croce
Member of Scientific Advisory Boardno datano datano data
Riccardo Dalla-Favera
Member of Scientific Advisory Board14.8yrsno datano data
Lale White
Independent Director4.8yrsUS$116.43k0.22%
€ 453.4k
Alberto Bardelli
Member of Scientific Advisory Board10.3yrsno datano data
Renee Tannenbaum
Independent Director3.6yrsUS$110.43k0.039%
€ 79.7k
Brunangelo Falini
Member of Scientific Advisory Board14.8yrsno datano data

10.4yrs

Average Tenure

72yo

Average Age

Experienced Board: XE7C's board of directors are seasoned and experienced ( 10.4 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 02:42
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cardiff Oncology, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raghuram SelvarajuAegis Capital Corporation
Sung Ji NamAvondale Partners
Bryan BrokmeierCantor Fitzgerald & Co.